Blueprint Medicines Aktie [WKN DE: A14SDD / ISIN: US09627Y1091]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Blueprint Medicines Corp

06.03.18		Blueprint Medicines to Present at Cowen and Company 38th Annual Health Care Conference (PR Newswire)
21.02.18		Blueprint Medicines Reports Fourth Quarter and Full Year 2017 Financial Results (PR Newswire)
14.02.18		Blueprint Medicines to Report Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 21, 2018 (PR Newswire)
13.12.17		ADRO Dumps CRS-207, Another Win For CoolSculpting, FDA Expands GSK's Nucala Use (RTTNews)
12.12.17		ARGX Soars, SNSS Catches Eyes, BPMC, BLUE Turn Heads, FDA Nod For SNNA (RTTNews)
11.12.17		Watch Out For BLUE, BPMC, GBT, KURA, KDMN, SYRS Today (RTTNews)
10.12.17		Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical Activity (PR Newswire)
05.12.17		ASH: BPMC To Make A Mark; FATE So Far, So Good; Watch Out For SYRS, BIVV (RTTNews)
30.11.17		Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors (PR Newswire)
10.11.17		Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors Showing Strengthened Clinical Activity across... (PR Newswire)
08.11.17		Blueprint Medicines to Present at Jefferies Global Healthcare Conference (PR Newswire)
03.11.17		ABUS Is Abuzz... (RTTNews)
02.11.17		Busy Year Awaits FLKS, Mark Your Calendar For BPMC Data, CLLS Loses Steam (RTTNews)
01.11.17		Blueprint Medicines Announces Publication of BLU-285 Translational Data (PR Newswire)
01.11.17		Blueprint Medicines to Present Updated Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Systemic Mastocytosis in Plenary Scientific Session at 59th ASH Annual Meeting... (PR Newswire)
31.10.17		Blueprint Medicines Reports Third Quarter 2017 Financial Results (PR Newswire)
24.10.17		Blueprint Medicines to Report Third Quarter 2017 Financial Results on Tuesday, October 31, 2017 (PR Newswire)
10.10.17		Blueprint Medicines Announces Appointment of Christopher Murray, Ph.D. as Senior Vice President, Technical Operations (PR Newswire)
14.09.17		TTOO Catches Investors' Eyes, SIEN Shaping Up, AGTC Slips Into Red (RTTNews)
11.09.17		New Hope For AZN's Old Drug, More About BMY's Opdivo, IMDZ On Watch (RTTNews)
10.09.17		Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma (PR Newswire)
06.09.17		Blueprint Medicines to Present at Morgan Stanley 15th Annual Global Healthcare Conference (PR Newswire)
23.08.17		Gainers & Losers Of Aug.22: OVID, SNNA, BPMC, ABIO, TOCA... (RTTNews)
22.08.17		FDA Approves IRWD's Gout Drug, It's A Thumbs Up For ALXN In EU, CRME Crushed (RTTNews)
21.08.17		Blueprint Medicines to Present Updated Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma at ESMO 2017 Congress and 11th ILCA Annual Conference (PR Newswire)
14.08.17		Stock Performance Review on Biotech Industry -- Blueprint Medicines, Calithera Biosciences, Concordia Intl., and Cytokinetics (PR Newswire)
03.08.17		Blueprint Medicines to Present at Upcoming Investor Conferences in August (PR Newswire)
02.08.17		Blueprint Medicines Reports Second Quarter 2017 Financial Results (PR Newswire)
27.07.17		Blueprint Medicines to Evaluate Opportunities to Advance Rare Disease Discovery Program in Fibrodysplasia Ossificans Progressiva Following Discontinuation of Collaboration with Alexion (PR Newswire)
26.07.17		Blueprint Medicines to Report Second Quarter 2017 Financial Results on Wednesday, August 2, 2017 (PR Newswire)
06.07.17		Gainers & Losers Of July 5: CALA, NVRO, BPMC, KMPH, FLDM... (RTTNews)
05.06.17		Blueprint Medicines Announces New Phase 1 Clinical Data for BLU-285 in Advanced Gastrointestinal Stromal Tumors and Plans to Pursue Expedited Development in Patients with a PDGFRα D842V Mutation (PR Newswire)
18.05.17		SNDX Rises On Entinostat Data, Kalydeco Gets FDA Nod, Concert Fails To Enthrall (RTTNews)
17.05.17		Blueprint Medicines to Present New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors at 2017 ASCO Annual Meeting (PR Newswire)
03.05.17		Blueprint Medicines Reports First Quarter 2017 Financial Results (PR Newswire)
26.04.17		Blueprint Medicines to Report First Quarter 2017 Financial Results on Wednesday, May 3, 2017 (PR Newswire)
04.04.17		Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock (PR Newswire)
30.03.17		Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock (PR Newswire)
29.03.17		Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock (PR Newswire)
27.03.17		Blueprint Medicines to Present on BLU-285 and BLU-554 at Upcoming Scientific Conferences (PR Newswire)
20.03.17		Blueprint Medicines Announces Enrollment of First Patient in Phase 1 Clinical Trial for BLU-667 (PR Newswire)
09.03.17		Blueprint Medicines Reports Fourth Quarter and Full Year 2016 Financial Results (PR Newswire)
02.03.17		Blueprint Medicines to Report Fourth Quarter and Full Year 2016 Financial Results on Thursday, March 9, 2017 (PR Newswire)
28.02.17		Blueprint Medicines to Present at Upcoming Investor Conferences in March (PR Newswire)
15.02.17		Blueprint Medicines to Present at 2017 RBC Capital Markets Global Healthcare Conference (PR Newswire)
13.12.16		Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock (PR Newswire)
08.12.16		Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock (PR Newswire)
06.12.16		Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock (PR Newswire)
01.12.16		It's All Green For BLUE, HTBX Plunges On Failed Study, Watch Out For BPMC (RTTNews)
01.12.16		Blueprint Medicines Announces Proof-of-Concept Data from Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors (PR Newswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Ripple auf dem Weg zu 100 US-Dollar in 2025?

Krypto-Rekorde voraus: Wall Street sieht Bitcoin bei 200.000 US-Dollar

Bitcoin Kurs Prognose: 150.000 US-Dollar in wenigen Tagen?

Starke Aussichten? So könnten sich die Magnificent 7-Aktien, inklusive NVIDIA, 2025 entwickeln

RBI-Aktie unter Druck: Russisches Urteil zu STRABAG zwingt RBI-Tochter zu Rückstellung

Trump ruft eigenen Krypto-Coin "$TRUMP" ins Leben - Kryptocoin auch für Melania

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	21.01.2025 15:36
Kaufwert:	EUR
	Hinzufügen Speichern